SCHOTT Announces Plans to Expand Pharmaceutical Packaging Capacities
SCHOTT’s production capacities for pharmaceutical packaging will be significantly increased, particularly in Europe and Asia.
SCHOTT recently announced that it is set to invest around €300 million (approximately $340 million) in the next three years in the expansion of its core business of glass tubing as the starting material for pharmaceutical packaging, as well as pharmaceutical packaging made of glass and polymer, reinforcing its strong belief in the overall demand growth for these products. Production capacities will be significantly increased, particularly in Europe and Asia.
“Today, we produce pharmaceutical glass tubing that is converted into approximately 25 billion pharmaceutical packages, such as vials, syringes, ampoules, or cartridges, produced by SCHOTT and other suppliers around the world,” said Frank Heinricht, Ph.D., chairman of the board of management. “Due to the strong demand for our products, we intend to further expand our leading position. We are now sending a signal that we are strengthening our presence in Asia. As a supplier, we are also contributing further to improving access to safe medication for local populations with these investments.”
According to SCHOTT, strong demand for its FIOLAX® glass tubing has prompted the construction of a new plant in Jinyun County, Zhejiang Province, China, which is scheduled to start production in 2020 and will serve the Chinese market. The investments in the coming years for this plant will amount to a three-digit million amount. SCHOTT has more than 900 employees at several locations in China and will create 300 new jobs by opening the new plant.
Constructing the new melting tank will also allow the company to expand its production capacity for FIOLAX at its pharmaceutical glass plant in Jambusar, Gujarat, India. The investment volume, including the new hall, energy supply, and warehouse, amounts to more than €20 million (~ $22.7 million). The investment also involves the creation of around 70 new jobs; a total of 380 people will be employed at the plant. The melting tank is scheduled to begin operation in early 2020.
As a result of strong market demand for prefillable polymer syringes, SCHOTT will expand respective production capacity at its sites in St. Gallen, Switzerland, and Müllheim, Germany. New production lines for polymer syringes have been constructed and put into operation at the St. Gallen plant since the middle of 2018. SCHOTT employs 500 people at the site.
In addition, a three-digit million euro amount is being invested in a new production facility for prefillable polymer syringes in Müllheim. The SCHOTT site’s 250 employees currently produce mostly pharmaceutical vials made of glass. A new production hall, an administrative building, and a pilot center will be built adjacent to the existing plant by 2022, creating approximately 100 additional jobs.
Additional details are available at www.schott.com.